Oramed Refines Portfolio Strategy as Russell Index Inclusion Looms

CEO Nadav Kidron outlined a pivot from a single-focus drug developer to a diversified holding company. The firm’s current portfolio is anchored by a significant stake in Alpha Tau Medical, where an investment of roughly $38.2 million has appreciated to approximately $167 million. This growth is bolstered by a recent commercialization deal between Alpha Tau and Tolmar, targeting the U.S. prostate cancer market.

Financial discipline has also defined the company’s recent activity regarding its debt holdings. Oramed has recouped roughly $118 million from a $99.5 million loan provided to Scilex Holding, with an additional $43 million expected by October 2026. Beyond these core assets, the company maintains interests in Lifeward, Nano Dimension, and BioXcel Therapeutics. These shifts, including the divestment of its oral insulin program to Lifeward, are intended to leverage Oramed’s regulatory and operational expertise to unlock value across the biomedical sector while maintaining a strong balance sheet.